Table 2.

Cases of subcutaneous and pulmonary nodulosis in patients receiving anti-TNF-α agents.

ReportLocation of NodulesAge, SexAnti-TNF-α and delayAssociated TreatmentPreexisting NodulesClinical SymptomsBiopsyTreatmentOutcome
Mackley2SCIFX (1 yr)NoNodules of handsRNNDND
Cunnane3SC52 META (2 mo)CSSCDevelopment of new cutaneous nodulesNoMaintenance of ETANo progression of nodules
SC50 M(3 mo)CSSCDevelopment of new cutaneous nodulesNoMaintenance of ETAResolution of pulmonary
Lungs67 M(2 mo)CSPulmonary noduleDyspnea: cavitating pulmonary nodulesRNETA discontinuednodules
Scrivo8SC45 FADA (2 yrs)CSNoNodules of elbowsNoMaintenance of ADANo progression of nodules
Kekow9SC and lungs53 FETA (7 mo)CSNoNodules of hands and elbows; nodular lesion on chest radiographRNETA discontinuedDiminished size of nodules
Hübscher10SC and lung41 FETA (yr)LEF + CSSCDevelopment of new cutaneous nodules and appearance of nodular lung lesionRNETA discontinuedND
Van Ede11Lungs50 META (2 yrs)LEFSCNodular lesions on chest radiographRNETA discontinuedResolution of cutaneous and pulmonary nodules
Watson12Lungs57 FETA (1 yr)LEF + CSNoDry coughNoETA maintainedNo progression of nodules
  • SC: subcutaneous; CS: corticosteroids; LEF: leflunomide; MTX: methotrexate; RN: rheumatoid nodule; ND: not determined.